-
Kamari Pharma Completes $8M Investment from Chinese Fund GIBF2
•
Israel-based Kamari Pharma has announced the completion of an $8 million investment from the Chinese fund GIBF2. This brings the total funds raised by Kamari to $16 million. The company was established at the end of 2018 by leading Israel-based biotech funds Pontifax and Arkin Bioholdings. Kamari develops topical and…
-
Joincare’s Modified Drug XYP-001 Gains NMPA Approval for IPF Trial
•
China-based Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its modified drug XYP-001 inhaler. The targeted indication is idiopathic pulmonary fibrosis (IPF). Disease Overview and Current TherapiesIPF is a chronic progressive fibrotic interstitial…
-
Koutech Robotics Secures Series A Funding for Surgical Innovation
•
China-based Koutech Robotics (Shanghai) Co., Ltd, a leading ultra-micro, high-precision surgical robot platform company, has reportedly raised “hundreds of millions” of renminbi in a Series A financing round. The round was led by Qiming Venture Partners, with contributions from Proxima Ventures, DNE Capital, Lingang Blue Bay Fund, Winfast Holding, and…
-
CARsgen Therapeutics Presents Positive Phase Ib/II Data for CT053 at CAR-TCR Summit
•
China-based CARsgen Therapeutics Holdings Ltd presented the results of a multi-center, open-label Phase Ib/II study assessing the safety and efficacy of its B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR) T cell therapy CT053 (zevor-cel) at the 7th CAR-TCR Annual Summit. The study is being conducted across North America, focusing…
-
Joincare Pharmaceuticals Prices GDRs on SIX Swiss Exchange
•
China-based Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) has priced its Global Depository Receipts (GDRs) on the SIX Swiss Exchange at $14.42 per share. The company aims to raise $92.04 million through the issuance of 638.25 million GDRs. GDR Issuance DetailsThe GDRs will be available for trading on September…
-
Northeast Pharmaceutical to Invest in Shanghai Subsidiary for ADC and CAR-T Development
•
China-based Northeast Pharmaceutical Co., Ltd (SHE: 000597) has announced plans to invest RMB 500 million ($71 million) in establishing a wholly-owned subsidiary in Shanghai. The new entity is designed to accelerate the implementation of in-licensed antibody drug conjugates (ADCs) and chimeric antigen receptor (CAR)-T cell therapies, following a recent ADC-focused…
-
Beijing Designates 923 Medical Entities for National Reimbursement Drug List
•
The Beijing Municipal Medical Insurance Bureau has released a notification indicating that a total of 923 medical entities are now designated for coverage under the National Reimbursement Drug List (NRDL). The document is open for public feedback from September 19 to September 26. Designated EntitiesAmong the designated entities are 169…
-
Lee’s Pharmaceutical Reports H1 Revenue Growth Amid Product Portfolio Shift
•
China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) has released its H1 2022 interim financial report, recording HKD 649 million ($82.6 million) in revenue, up 11.1% year-on-year (YOY). The growth was driven by products such as Bredinin (mizoribine), treprostinil, and interferon α2b, which offset declining sales of Ferplex (iron protein succinylate)…
